VORICONAZOLO 200 mg Порошок И Раствор Для Инфузионного Раствора

Содержание инструкции

1. Voriconazolo Ibisqus 200 mg powder for solution for infusion
   1. What is Voriconazolo Ibisqus and what it is used for
   2. What you need to know before taking Voriconazolo Ibisqus
   3. How to take Voriconazolo Ibisqus
   4. Possible side effects
   5. How to store Voriconazolo Ibisqus
   6. Contents of the pack and other information

Voriconazolo Ibisqus 200 mg powder for solution for infusion

Generic medicine

Read this leaflet carefully before you start this medicine because it contains
important information for you.

• Keep this leaflet. You may need to read it again
• If you have any questions, ask your doctor, pharmacist or nurse
• This medicine has been prescribed for you only. Do not pass it on to others, even if their symptoms are the same as yours, as it could be harmful
• If you get any side effects, even those not listed in this leaflet, tell your doctor, pharmacist or nurse. See section 4

Contents of this leaflet

• 1. What Voriconazolo Ibisqus is and what it is used for
• 2. What you need to know before you are given Voriconazolo Ibisqus
• 3. How to use Voriconazolo Ibisqus
• 4. Possible side effects
• 5. How to store Voriconazolo Ibisqus
• 6. Contents of the pack and other information

1. What is Voriconazolo Ibisqus and what it is used for

Voriconazolo Ibisqus contains the active ingredient voriconazole. Voriconazolo Ibisqus is an antifungal medicine.
It works by stopping the growth or killing fungi that cause infections.
It is used for the treatment of patients (adults and children over 2 years of age) suffering from:

• invasive aspergillosis (a type of fungal infection caused by species of Aspergillus)
• candidemia (another type of fungal infection caused by species of Candida) in non-neutropenic patients (patients who do not have an unusually low white blood cell count)
• severe and invasive infections caused by species of Candida, when the fungus is resistant to fluconazole (another antifungal active ingredient)
• severe fungal infections caused by species of Scedosporiumand Fusarium(two different species of fungi)

Voriconazolo Ibisqus is indicated for patients with worsening fungal infections and
potentially life-threatening conditions.
Prevention of fungal infections in patients undergoing high-risk bone marrow transplantation.
This product must be used only under medical supervision.

2. What you need to know before taking Voriconazolo Ibisqus

Do not take Voriconazolo Ibisqus:
if you are allergic to the active ingredient voriconazole or to sodium sulfobutylether beta-cyclodextrin (listed
in section 6).
It is very important that you inform your doctor or pharmacist if you are taking or have taken other
medicines, even those without a prescription, or herbal medicines.
The medicines included in the list below should not be used during
treatment with Voriconazolo Ibisqus:

• Terfenadine (for allergies)
• Astemizole (for allergies)
• Cisapride (for stomach problems)
• Pimozide (for the treatment of mental illnesses)
• Quinidine (for irregular heartbeat)
• Ivabradine (for symptoms of chronic heart failure)
• Rifampicin (for the treatment of tuberculosis)
• Efavirenz (for the treatment of AIDS) in doses equal to or greater than 400 mg once a day
• Carbamazepine (for the treatment of seizures)
• Phenobarbital (for severe insomnia and seizures)
• Ergot alkaloids (e.g., ergotamine, dihydroergotamine; for migraine)
• Sirolimus (for patients undergoing transplantation)
• Ritonavir (for the treatment of AIDS) in doses of 400 mg and over, twice a day
• St. John's Wort (hypericum - herbal medicinal product supplement)
• Naloxegol (for the treatment of constipation specifically caused by pain medications, called opioids [e.g. morphine, oxycodone, fentanyl, tramadol, codeine])
• Tolvaptan (for the treatment of hyponatremia, i.e. low sodium levels in the blood, or to slow the decline of kidney function in patients with polycystic kidney disease)
• Lurasidone (for the treatment of depression)
• Venetoclax (for the treatment of patients with chronic lymphocytic leukemia-CLL)

Warnings and precautions
Talk to your doctor, pharmacist or nurse before taking Voriconazolo Ibisqus if:

• you have had an allergic reaction to other azoles
• you suffer from or have suffered from a liver disease. If you have liver problems, your doctor may prescribe a lower dose of Voriconazolo Ibisqus. Your doctor will need to check your liver function during treatment with Voriconazolo Ibisqus by performing blood tests
• you know you have heart disease, an irregular heartbeat, a slowed heartbeat or an abnormality in your electrocardiogram (ECG) called “long QT syndrome”

You should avoid any exposure to the sun and sunlight during treatment. It is important to cover
skin areas exposed to the sun and use sunscreens with a high protection factor (SPF), as increased
skin sensitivity to UV rays from the sun may occur. These precautions also apply
to children.
During treatment with Voriconazolo Ibisqus, immediately inform your doctor if you develop:

• sunburn
• severe skin reaction or blisters
• bone pain

If you develop any of the skin conditions described above, your doctor may refer you to a
dermatologist, who after consultation may decide that it is important to have you undergo regular visits.
Prolonged use of Voriconazolo Ibisqus is associated with a small risk of developing a
skin cancer.
If you develop signs of “adrenal insufficiency”, in which the adrenal glands do not produce
adequate amounts of some steroid hormones such as cortisol, which can cause symptoms such as
chronic or persistent fatigue, muscle weakness, loss of appetite, weight loss, abdominal pain, inform
your doctor.
Inform your doctor if you develop signs of “Cushing's syndrome” in which the body produces excessive amounts
of the hormone cortisol, which can cause symptoms such as weight gain, fat accumulation
between the shoulders, a rounded face, darkening of the skin of the abdomen, thinning of legs,
breasts and arms, thinning of the skin, easy bruising, increased blood sugar levels, excessive hair growth on the body, excessive sweating.
Your doctor will need to check your liver and kidney function by performing blood tests.

Children and adolescents
Voriconazolo Ibisqus should not be given to children under 2 years of age.

Other medicines and Voriconazolo Ibisqus
Tell your doctor or pharmacist if you are taking, have recently taken or might take
any other medicines, even those without a prescription.
Some medicines, when taken at the same time as Voriconazolo Ibisqus, can change
the activity of Voriconazolo Ibisqus or Voriconazolo Ibisqus can change the activity of these
medicines.
Tell your doctor if you are taking the following medicine because, if possible, concomitant treatment with Voriconazolo Ibisqus should be avoided:

• Ritonavir (for the treatment of AIDS) in doses of 100 mg twice a day
• Glasdegib (for the treatment of cancer): if you need to use both drugs, your doctor will often check your heart rate

Tell your doctor if you are taking any of the following medicines because, if possible, concomitant treatment with Voriconazolo Ibisqus should be avoided and a dose adjustment of voriconazole may be necessary:

• Rifabutin (for the treatment of tuberculosis). If you are already being treated with rifabutin, the blood cell count and side effects of rifabutin should be monitored.
• Phenytoin (for the treatment of epilepsy). If you are already being treated with phenytoin, phenytoin levels in the blood should be monitored during treatment with Voriconazolo Ibisqus and the dose you are taking may be adjusted.

Tell your doctor if you are taking any of these medicines because a dose adjustment or monitoring of the dose may be necessary to verify that these medicines and/or Voriconazolo
Ibisqus continue to have the desired effect:

• Warfarin and other anticoagulants (e.g., phenprocoumon, acenocoumarol) (to slow down blood clotting)
• Cyclosporine (for patients undergoing transplantation)
• Tacrolimus (for patients undergoing transplantation)
• Sulfonylureas (e.g., tolbutamide, glipizide and gliburide) (for diabetes)
• Statins (e.g., atorvastatin, simvastatin) (to reduce cholesterol)
• Benzodiazepines (e.g., midazolam, triazolam) (for severe insomnia and stress)
• Omeprazole (for the treatment of ulcers)
• Oral contraceptives (if you take Voriconazolo Ibisqus during treatment with oral contraceptives, side effects such as nausea and menstrual disorders may occur)
• Vinca alkaloids (e.g., vincristine and vinblastine) (for the treatment of cancer)
• Tyrosine kinase inhibitors (e.g. axitinib, bosutinib, cabozantinib, ceritinib, cobimetinib, dabrafenib, dasatinib, nilotinib, sunitinib, ibrutinib, ribociclib) (for the treatment of cancer)
• Tretinoin (for the treatment of leukemia)
• Indinavir and other AIDS protease inhibitors (for the treatment of AIDS)
• Non-nucleoside reverse transcriptase inhibitors (e.g., efavirenz, delavirdine, nevirapine) (for the treatment of AIDS) (some doses of efavirenz CANNOT be taken with Voriconazolo Ibisqus)
• Methadone (for the treatment of heroin addiction)
• Alfentanil and fentanyl and other short-acting opioids such as sufentanil (pain relievers used for surgical techniques)
• Oxycodone and other long-acting opioids such as hydrocodone (used for the treatment of moderate to severe pain)
• Non-Steroidal Anti-Inflammatory Drugs (e.g., ibuprofen, diclofenac) (used for the treatment of pain and inflammation)
• Fluconazole (used to treat fungal infections)
• Everolimus (used for the treatment of advanced kidney cancer and in patients undergoing transplantation)
• Letermovir (used to prevent cytomegalovirus (CMV) disease following bone marrow transplantation)
• Ivacaftor: used for the treatment of cystic fibrosis
• Flucloxacillin (antibiotic indicated in bacterial infections)

Pregnancy and breastfeeding
Voriconazolo Ibisqus should not be taken during pregnancy unless decided
by your doctor. Women of childbearing potential must use adequate contraception. Contact
your doctor immediately if you become pregnant during treatment with Voriconazolo Ibisqus.
If you are pregnant or breastfeeding, if you suspect or are planning a
pregnancy, ask your doctor or pharmacist for advice before taking this medicine.

Driving and using machines
Voriconazolo Ibisqus can cause blurred vision or a bothersome sensitivity to light. In such
cases, you should not drive and should not use tools or machinery. Contact your doctor in these cases.

Voriconazolo Ibisqus contains sodium
Each vial of this medicine contains 216-228 mg of sodium (the main component of table
salt) equivalent to 10.8-11.4% of the recommended maximum daily intake with the diet of
an adult.

Voriconazolo Ibisquscontains cyclodextrin
This medicine contains 3,200 mg of cyclodextrins per vial equivalent to 160 mg/ml when
reconstituted in 20 ml. If you have kidney problems, talk to your doctor before taking this
medicine.

3. How to take Voriconazolo Ibisqus

Take this medicine following exactly the instructions of your doctor. If you have any doubts, consult your doctor.
The doctor will establish the appropriate dose for you based on your weight and the type of infection diagnosed.
The doctor may adjust the dose based on your condition.
The recommended dose for adults (including elderly patients) is as follows:

Based on the response to treatment, the doctor may decrease the dose to 3 mg/kg twice a day.
If you have mild to moderate cirrhosis, the doctor may decide to reduce the dose.

Use in children and adolescents
The recommended dose in children and adolescents is as follows:

Based on the response to treatment, the doctor may increase or decrease the daily dose.
Voriconazolo Ibisqus powder for solution for infusion will be reconstituted and diluted by the pharmacist or
hospital nurse to obtain the correct concentration. (For further information
The medicine will be administered to you by intravenous infusion (into a vein) at a maximum infusion rate of
3 mg/kg/h over 1-3 hours.
If you or your child are taking Voriconazolo Ibisqus for the prevention of fungal infections, your
doctor may decide to discontinue the administration of Voriconazolo Ibisqus if you or your
child should develop adverse effects related to treatment.

If you forget to take a dose of Voriconazolo Ibisqus
Since this medicine will be administered under medical supervision, it is unlikely that a dose will be missed.
However, if you think a dose has been forgotten, report it to your doctor or pharmacist.

If you stop taking Voriconazolo Ibisqus
Treatment with Voriconazolo Ibisqus must continue as long as your doctor decides; however, the
duration of treatment with Voriconazolo Ibisqus powder for solution for infusion should not exceed
6 months. Patients with a weakened immune system or those who have infections that are difficult to
treat may require long-term treatment to prevent the infection from returning. When
your condition improves, you may be able to switch from intravenous treatment to tablets.
When treatment with Voriconazolo Ibisqus is stopped at the request of the doctor, no effects should occur.
If you have any doubts about the use of this medicine, ask your doctor, pharmacist or
nurse.

4. Possible side effects

Like all medicines, this medicine can cause side effects, although not everyone gets them.
If side effects occur, most will likely be mild and
transient. However, some may be serious and require medical attention.

Serious side effects - Stop taking Voriconazolo Ibisqus and consult your doctor immediately

• skin rash
• jaundice, changes in liver function tests
• pancreatitis

Other side effects
Very common: may affect more than 1 in 10 people

• impaired vision (changes in vision including blurred vision, altered color vision, abnormal intolerance to the visual perception of light, color blindness, eye disease, halo vision, night blindness, oscillating vision, seeing sparks, visual aura, reduced visual acuity, visual brightness, partial loss of visual field, spots in front of the eyes)
• fever
• skin rashes
• nausea, vomiting, diarrhea
• headache
• swelling of the extremities
• stomach pain
• difficulty breathing
• elevated liver enzymes

Common: may affect 1 in 10 people

• inflammation of the paranasal sinuses, inflammation of the gums, chills, fatigue
• reduction, even severe, in the number of some types of red blood cells (sometimes immune-related) and/or white blood cells (sometimes with fever), reduction in the number of blood cells (called platelets) that help blood clotting
• low blood sugar levels, low blood potassium levels, low blood sodium levels
• anxiety, depression, confusion, agitation, sleep disorders, hallucinations
• convulsions, tremor or uncontrolled muscle movements, tingling or abnormal skin sensations, increased muscle tone, drowsiness, dizziness
• bleeding in the eye
• irregular heartbeat including very fast heartbeat, very slow heartbeat, fainting
• low blood pressure, inflammation of a vein (which may be associated with the formation of a blood clot)
• acute difficulty breathing, chest pain, swelling of the face (mouth, lips and around the eyes), fluid accumulation in the lungs
• constipation, indigestion, inflammation of the lips
• jaundice, inflammation of the liver and liver damage
• skin rash that may involve blistering and severe skin peeling, characterized by a flat and reddened area of skin with confluent small bumps, skin redness
• itching
• hair loss
• back pain
• kidney failure, blood in the urine, changes in kidney function tests

Uncommon: may affect 1 in 100 people

• flu-like symptoms, irritation and inflammation of the gastrointestinal tract, inflammation of the gastrointestinal tract that can cause antibiotic-associated diarrhea, inflammation of the lymphatic vessels
• inflammation of the thin tissue lining the inner wall of the abdomen and covering the abdominal organ
• enlarged lymph nodes (sometimes painful), bone marrow failure, increased eosinophils
• reduced function of the adrenal glands, reduced activity of the thyroid gland
• changes in brain function, Parkinson's-like symptoms, nerve damage resulting in numbness, pain, tingling or burning in the hands or feet
• problems with balance and coordination
• brain edema
• double vision, serious eye conditions including: pain and inflammation of the eyes and eyelids, abnormal eye movement, damage to the optic nerve with impaired vision, swelling of the optic disc
• reduced sensitivity to touch
• altered taste
• hearing disorders, ringing in the ears, vertigo
• inflammation of some internal organs, pancreas and duodenum, swelling and inflammation of the tongue
• enlarged liver, liver failure, gallbladder diseases, gallstones
• inflammation of the joints, inflammation of the superficial veins (which may be associated with the formation of blood clots)
• inflammation of the kidneys, presence of protein in the urine, kidney damage
• very fast heartbeat or missed beats, sometimes with irregular electrical impulses
• altered electrocardiogram (ECG)
• increased cholesterol, increased urea in the blood
• allergic skin reactions (sometimes severe) including a potentially life-threatening skin condition causing blisters and painful sores on the skin and mucous membranes, especially in the mouth, skin inflammation, hives, sunburn or severe skin reaction following exposure to light or sun, skin redness and irritation, skin discoloration (red or purple) which may be caused by a low platelet count, eczema
• infusion site reaction
• allergic reactions or exaggerated immune response

Rare: may affect 1 in 1000 people

• hyperactive thyroid gland
• deterioration of brain function as a serious complication of liver disease
• loss of a large portion of the nerve fibers of the optic nerve, corneal opacity, involuntary eye movement
• bullous photosensitivity
• disorder in which the body's immune system attacks a part of the peripheral nervous system
• heart rhythm or conduction problems (sometimes fatal)
• potentially life-threatening allergic reaction
• disorders of the blood coagulation system
• allergic skin reactions (sometimes severe), including rapid swelling (edema) of the dermis, subcutaneous tissue, mucosa and submucosal tissues, itchy or painful patches of thickened and reddened skin with silvery scales, skin irritation and mucous membranes, a potentially life-threatening skin condition causing the detachment of large areas of the epidermis (the outer layer of skin) from the underlying skin layers
• small patches of dry, scaly skin, sometimes thick with points or ‘horns’

Side effects with unknown frequency

• freckles and pigmented spots

Other significant side effects, whose frequency is unknown but which should be reported
immediately to the doctor are:

• skin cancer
• inflammation of the tissues surrounding the bones
• red, scaly or ring-shaped skin lesions that may be symptoms of an autoimmune disease called systemic lupus erythematosus

The onset of reactions (including skin redness, fever, sweating, increased heart rate and shortness of
breath) during the infusion of Voriconazolo Ibisqus is not common. If one or more of these reactions
occur, your doctor may decide to stop the infusion.
Since Voriconazolo Ibisqus has been shown to have effects on the liver and kidneys, the doctor will need
to monitor liver and kidney function by performing blood tests. Tell your doctor if you have
stomach pain or if your stools are of a different consistency than usual.
Cases of skin cancer have been reported in patients treated with Voriconazolo Ibisqus for prolonged
periods.
Sunburn or a severe skin reaction following exposure to light or sun has been
reported more frequently in children. If you or your child develops skin disorders, your
doctor may have you or your child visit a dermatologist who can decide whether it is important for you or
your child to continue regular visits with the dermatologist. Elevated liver enzymes have also
been observed more frequently in children.
If any of these side effects persist or are bothersome, tell your doctor.

Reporting of side effects
If you get any side effects, even if not listed in this leaflet, tell your
doctor, pharmacist or healthcare professional. You can also report side effects
directly through the national reporting system at
https://www.aifa.gov.it/content/segnalazioni-reazioni-avverse
By reporting side effects you can help provide more information on the safety of
this medicine.

5. How to store Voriconazolo Ibisqus

Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the label. The expiry date
refers to the last day of that month.
This medicine does not require any special storage conditions.
Once reconstituted, Voriconazolo Ibisqus must be used immediately, but if necessary
it may be stored for up to 24 hours at a temperature between 2°C and 8°C (in a refrigerator). The
solution of Voriconazolo Ibisqus reconstituted must be diluted with a compatible diluent for
intravenous infusion before administration. (For further information see the paragraph
Do not dispose of any medicine in wastewater or household waste. Ask your pharmacist how to
dispose of medicines you no longer use. This will help protect the environment.

6. Contents of the pack and other information

What Voriconazolo Ibisqus contains
The active ingredient is voriconazole.
The other component is sulfobutylether beta cyclodextrin sodium and sodium hydroxide (see paragraph 2,
Voriconazolo Ibisqus 200 mg powder for solution for infusion contains cyclodextrin and sodium).
Each vial contains 200 mg of voriconazole, equivalent to a solution of 10 mg/ml, when
reconstituted as recommended by the pharmacist or hospital nurse (see the information

Description of the appearance of Voriconazolo Ibisqus and contents of the pack
Voriconazolo Ibisqus is packaged in single-use glass vials containing a powder for
solution for infusion.
Pack: 1 vial

Marketing Authorisation Holder
Istituto Biochimico Italiano G. Lorenzini S.p.A.
Via Fossignano 2 - Aprilia (LT) – Italy
e-mail: [email protected]

Manufacturer
Istituto Biochimico Italiano G. Lorenzini S.p.A.
Via Fossignano 2 - Aprilia (LT) – Italy

---------------------------------------------------------------------------------------------------------------------------
The following information is intended exclusively for healthcare professionals
Information on reconstitution and dilution

• Voriconazolo Ibisqus powder for solution for infusion must be initially reconstituted with 19 ml of water for injections or with 19 ml of a Sodium Chloride 9 mg/ml (0.9%) solution for infusion to obtain a withdrawable volume of 20 ml of a clear concentrate containing 10 mg/ml of voriconazole
• Do not use the vial of Voriconazolo Ibisqus if the internal vacuum negative pressure does not aspirate the diluent into the vial itself
• It is recommended to use a standard 20 ml syringe (non-automatic) in order to guarantee the administration of the exact amount of water for injections (19.0 ml) or the Sodium Chloride 9 mg/ml (0.9%) solution for infusion
• The necessary volume of reconstituted concentrate is then added to one of the compatible infusion solutions listed below in order to obtain a Voriconazolo Ibisqus solution containing 0.5-5 mg/ml of voriconazole
• This medicine is for single use only and unused solution must be discarded and only clear solutions free of particles must be used
• The product must not be administered as a bolus
• For information on product storage, please refer to Paragraph 5 “How to store Voriconazolo Ibisqus”

Required volumes of Voriconazolo Ibisqus 10 mg/ml concentrate

Volume of Voriconazolo Ibisqus concentrate (10 mg/ml) required for
Weight
Body
Dose of 3 mg/kgDose of 4 mg/kgDose of 6 mg/kgDose of 8 mg/kgDose of 9 mg/kg
(number of(number of(number of(number of(number of
(kg)vials)vials)vials)vials)vials)

• 10 - 4.0 ml (1) - 8.0 ml (1) 9.0 ml (1)
• 15 - 6.0 ml (1) - 12.0 ml (1) 13.5 ml (1)
• 20 - 8.0 ml (1) - 16.0 ml (1) 18.0 ml (1)
• 25 - 10.0 ml (1) - 20.0 ml (1) 22.5 ml (2) 30 9.0 ml (1) 12.0 ml (1) 18.0 ml (1) 24.0 ml (2) 27.0 ml (2) 35 10.5 ml (1) 14.0 ml (1) 21.0 ml (2) 28.0 ml (2) 31.5 ml (2) 40 12.0 ml (1) 16.0 ml (1) 24.0 ml (2) 32.0 ml (2) 36.0 ml (2) 45 13.5 ml (1) 18.0 ml (1) 27.0 ml (2) 36.0 ml (2) 40.5 ml (3) 50 15.0 ml (1) 20.0 ml (1) 30.0 ml (2) 40.0 ml (2) 45.0 ml (3) 55 16.5 ml (1) 22.0 ml (2) 33.0 ml (2) 44.0 ml (3) 49.5 ml (3) 60 18.0 ml (1) 24.0 ml (2) 36.0 ml (2) 48.0 ml (3) 54.0 ml (3) 65 19.5 ml (1) 26.0 ml (2) 39.0 ml (2) 52.0 ml (3) 58.5 ml (3) 70 21.0 ml (2) 28.0 ml (2) 42.0 ml (3) - - 75 22.5 ml (2) 30.0 ml (2) 45.0 ml (3) - - 80 24.0 ml (2) 32.0 ml (2) 48.0 ml (3) - - 85 25.5 ml (2) 34.0 ml (2) 51.0 ml (3) - - 90 27.0 ml (2) 36.0 ml (2) 54.0 ml (3) - - 95 28.5 ml (2) 38.0 ml (2) 57.0 ml (3) - - 100 30.0 ml (2) 40.0 ml (2) 60.0 ml (3) - -

Voriconazolo Ibisqus is a sterile, lyophilized powder for single dose use without preservatives. Therefore, from
a microbiological point of view, the reconstituted solution must be used
immediately.
If not used immediately, the storage conditions before and after opening the
pack are the responsibility of the healthcare personnel and the product must not be used after
24 hours from opening the pack stored at a temperature of 2-8°C, unless the
reconstitution has been carried out under controlled and validated aseptic conditions.

Compatible diluents
The reconstituted solution can be diluted with:

• Sodium Chloride 9 mg/ml (0.9%) Solution for Injection
• Sodium Lactate Compound Solution for Intravenous Infusion
• Glucose 5% and Ringer Lactate for Intravenous Infusion
• Glucose 5% and Sodium Chloride 0.45% for Intravenous Infusion
• Glucose 5% for Intravenous Infusion
• Glucose 5% in 20 mEq of Potassium Chloride for Intravenous Infusion
• Sodium Chloride 0.45% for Intravenous Infusion
• Glucose 5% and Sodium Chloride 0.9% for Intravenous Infusion

The compatibility of Voriconazolo Ibisqus with diluents other than those listed above (or
listed in the paragraph “Incompatibilities”) is not known.

Incompatibilities
Voriconazolo Ibisqus must not be administered in the same line or cannula together with other
medicines for intravenous infusion, including parenteral nutrition (e.g., Aminofusin
10% Plus).
The infusion of blood derivatives must not be carried out simultaneously with the administration of
Voriconazolo Ibisqus.
The infusion of total parenteral nutrition can be carried out simultaneously with the
administration of Voriconazolo Ibisqus, but not through the same infusion route.
Voriconazolo Ibisqus must not be diluted with Sodium Bicarbonate 4.2% Infusion.